Integrated Quality Control Processes for Cell Therapy Workflows Using Automated Solutions

CAR-T cell therapy research for B cell cancers must meet FDA guidelines for safety, efficacy, and stability. Accurate testing, including cytokine assays, is essential to avoid risks like cytokine-release syndrome in research settings. Development of cell and gene therapy research faces multiple bottlenecks, especially in the characterization and QC processes which are traditionally manual and time-consuming. The need for an automated solution to streamline the research workflow and minimize manual intervention is critical to improving throughput and consistency.

Automation of multiplexed immunoassays, like Invitrogen™ ProcartaPlex™ immunoassay with Thermo Scientific™ KingFisher Apex Purification system may offer ease of use and significantly reduce hands-on time requirements to evaluate cellular expansion in research settings. In QC processes, The KingFisher Apex can be utilized with Applied Biosystems™ MagMAX™ chemistries to isolate DNA and RNA sequentially from a single supernatant allowing streamlined workflows for assessment of quality performance in cell cultures in research settings. In this webinar, we will discuss innovative approaches to future CAR-T cell therapy development workflows by deploying automation and innovative sample preparation solutions to improve productivity and efficiency.

Key Learning Objectives

• Automation of cell therapy research workflows from discovery to preclinical stages
• Quantification of CAR-T targeted killing in research settings with multiplexed immunoassays on automation instruments
• Preservation of sample while enhancing productivity and workflows during QC of cell cultures post-transduction within future cell therapy development workflows